絞り込み

16555

広告

Differences in baseline characteristics between type 2 diabetes mellitus patients treated with dipeptidyl peptidase-4 inhibitors in randomized controlled trials and those receiving the same treatment in real-world settings
.

著者 Kostev K , Schokker E , Jacob L
Int J Clin Pharmacol Ther.2018 Jul 27 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (49view , 0users)

Full Text Sources

Miscellaneous

The goal was to analyze differences between the baseline characteristics of type 2 diabetes mellitus (T2DM) patients treated with dipeptidyl peptidase-4 (DPP-4) inhibitors in three randomized clinical trials (RCTs) and those receiving the same treatment in a German real-world setting.
PMID: 30049306 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード